Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
ASCO 2024 – AstraZeneca’s GPC3 secret sauce
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.
ASCO 2024 preview – new Car-T target shows liver cancer promise
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
ASCO-GI – some shine comes off Astra’s Emerald
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
